Severe early acute humoral rejection resulting in allograft loss in a renal transplant recipient with Campath-1H induction therapy

Abstract

One of the major goals in organ transplantation is to reduce immunosuppression by reprogramming the immune system so as to encourage tolerance. This process has been shown in animal models to be facilitated by lymphocyte depletion at the time of the transplant, and the degree of lymphocyte depletion substantially impacts the efficacy of such treatment [1,2]. Campath-1H is a humanized CD52-specific depleting complement-fixing cytotoxic IgG1 monoclonal antibody. CD52 antigen is located on the surface of T and B lymphocytes, natural killer (NK) cells, and less densely on monocytes [3]. Campath-1H profoundly depletes T lymphocytes from the peripheral blood for several months as well as having less marked effects on B lymphocytes, NK cells, monocytes and CD34-positive immature stem cells [3]. Campath-1H was initially used to treat acute renal allograft rejection [4] and later used successfully together with low dose cyclosporin (CsA) as induction therapy in renal transplantation [3]. Several other centres have also now reported their experiences with the use of Campath-1H together with various combinations of immunosuppressive agents in renal transplantation [5–9]. In some of the series there was a higher than usual incidence of acute humoral or antibody-mediated rejection (AHR) among the acute rejection (AR) episodes [6,8]. We report a case of early severe AHR resulting in renal allograft loss in a patient treated with Campath-1H induction therapy. Case